221 related articles for article (PubMed ID: 15542784)
1. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids.
Jensen SS; Andresen TL; Davidsen J; Høyrup P; Shnyder SD; Bibby MC; Gill JH; Jørgensen K
Mol Cancer Ther; 2004 Nov; 3(11):1451-8. PubMed ID: 15542784
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs.
Andresen TL; Davidsen J; Begtrup M; Mouritsen OG; Jørgensen K
J Med Chem; 2004 Mar; 47(7):1694-703. PubMed ID: 15027860
[TBL] [Abstract][Full Text] [Related]
3. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2.
Andresen TL; Jensen SS; Kaasgaard T; Jørgensen K
Curr Drug Deliv; 2005 Oct; 2(4):353-62. PubMed ID: 16305438
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological activity of anticancer ether lipids that are specifically released by phospholipase A2 in tumor tissue.
Andresen TL; Jensen SS; Madsen R; Jørgensen K
J Med Chem; 2005 Nov; 48(23):7305-14. PubMed ID: 16279790
[TBL] [Abstract][Full Text] [Related]
5. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.
Andresen TL; Jensen SS; Jørgensen K
Prog Lipid Res; 2005 Jan; 44(1):68-97. PubMed ID: 15748655
[TBL] [Abstract][Full Text] [Related]
6. Phospholipase A(2)-susceptible liposomes of anticancer double lipid-prodrugs.
Arouri A; Mouritsen OG
Eur J Pharm Sci; 2012 Mar; 45(4):408-20. PubMed ID: 21946258
[TBL] [Abstract][Full Text] [Related]
7. Revisiting the use of sPLA
Pourhassan H; Clergeaud G; Hansen AE; Østrem RG; Fliedner FP; Melander F; Nielsen OL; O'Sullivan CK; Kjær A; Andresen TL
J Control Release; 2017 Sep; 261():163-173. PubMed ID: 28662900
[TBL] [Abstract][Full Text] [Related]
8. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.
Huang ZR; Tipparaju SK; Kirpotin DB; Pien C; Kornaga T; Noble CO; Koshkaryev A; Tran J; Kamoun WS; Drummond DC
J Control Release; 2019 Sep; 310():47-57. PubMed ID: 31400383
[TBL] [Abstract][Full Text] [Related]
9. Secretory phospholipase A
Østrem RG; Parhamifar L; Pourhassan H; Clergeaud G; Nielsen OL; Kjær A; Hansen AE; Andresen TL
J Control Release; 2017 Sep; 262():212-221. PubMed ID: 28754610
[TBL] [Abstract][Full Text] [Related]
10. Enzymatic action of phospholipase A₂ on liposomal drug delivery systems.
Hansen AH; Mouritsen OG; Arouri A
Int J Pharm; 2015 Aug; 491(1-2):49-57. PubMed ID: 26056930
[TBL] [Abstract][Full Text] [Related]
11. Anticancer double lipid prodrugs: liposomal preparation and characterization.
Arouri A; Mouritsen OG
J Liposome Res; 2011 Dec; 21(4):296-305. PubMed ID: 21438721
[TBL] [Abstract][Full Text] [Related]
12. Nanoassemblies containing a fluorouracil/zidovudine glyceryl prodrug with phospholipase A2-triggered drug release for cancer treatment.
Jin Y; Yang F; Du L
Colloids Surf B Biointerfaces; 2013 Dec; 112():421-8. PubMed ID: 24036626
[TBL] [Abstract][Full Text] [Related]
13. Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy.
Gu Y; Ma J; Fu Z; Xu Y; Gao B; Yao J; Xu W; Chu K; Chen J
Int J Nanomedicine; 2019; 14():8805-8818. PubMed ID: 31806973
[TBL] [Abstract][Full Text] [Related]
14. Liposomes Targeting P21 Activated Kinase-1 (PAK-1) and Selective for Secretory Phospholipase A
Najahi-Missaoui W; Quach ND; Somanath PR; Cummings BS
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321758
[TBL] [Abstract][Full Text] [Related]
15. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic study of the sPLA2-mediated hydrolysis of a thio-ester pro anticancer ether lipid.
Linderoth L; Fristrup P; Hansen M; Melander F; Madsen R; Andresen TL; Peters GH
J Am Chem Soc; 2009 Sep; 131(34):12193-200. PubMed ID: 19663381
[TBL] [Abstract][Full Text] [Related]
17. Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors.
Fang T; Dong Y; Zhang X; Xie K; Lin L; Wang H
Int J Pharm; 2016 Oct; 512(1):39-48. PubMed ID: 27544846
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biophysical characterization of chlorambucil anticancer ether lipid prodrugs.
Pedersen PJ; Christensen MS; Ruysschaert T; Linderoth L; Andresen TL; Melander F; Mouritsen OG; Madsen R; Clausen MH
J Med Chem; 2009 May; 52(10):3408-15. PubMed ID: 19402667
[TBL] [Abstract][Full Text] [Related]
19. Prodrug strategy for cancer cell-specific targeting: A recent overview.
Zhang X; Li X; You Q; Zhang X
Eur J Med Chem; 2017 Oct; 139():542-563. PubMed ID: 28837920
[TBL] [Abstract][Full Text] [Related]
20. Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy.
Sundarraj S; Thangam R; Sujitha MV; Vimala K; Kannan S
Toxicol Appl Pharmacol; 2014 Mar; 275(3):232-43. PubMed ID: 24467950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
